Canine Leptospirosis: Understanding Epidemiology, Serovars, and Clinical Risk in Veterinary Practice

Leptospirosis remains one of the most widespread zoonotic diseases globally, affecting nearly all mammalian species and posing a dual burden on public health and veterinary medicine^1,2. For veterinarians, dogs occupy a unique position, not only as susceptible hosts but also as sentinel indicators of environmental risk to humans. Understanding its epidemiology and serovar diversity is critical for accurate diagnosis, prevention, and client education. 

Epidemiological Significance and Transmission Dynamics 

The epidemiology of leptospirosis is fundamentally driven by renal carrier animals that chronically shed leptospires into the environment via urine. This environmental contamination serves as a persistent source of infection for both animals and humans. While livestock and rodents are traditionally recognized as primary reservoirs, canine exposure must not be underestimated, especially in urban and peri-urban settings¹. 

Dogs are highly susceptible to infection and often mirror environmental exposure risks. Their close association with humans further amplifies zoonotic concerns, making early detection and preventive strategies essential components of veterinary care. 

Serovar Diversity and Clinical Relevance 

Leptospirosis is caused by over 230 serovars within at least ten pathogenic species of the Leptospira genus¹. However, not all serovars carry equal clinical importance in dogs. Seroprevalence studies highlight that the most predominant serogroups in canine populations include: 

• Canicola  

• Icterohaemorrhagiae  

• Australis  

• Grippotyphosa  

Additionally, regional variations exist, with Pomona being more relevant in the USA and Hebdomadis in Japan [4,6]. 

This diversity has direct clinical implications. Different serovars can vary in virulence, organ tropism, and clinical presentation, making it essential for veterinarians to consider regional epidemiology when diagnosing suspected cases. 

Pathogenesis and Clinical Expression 

Clinical leptospirosis develops when leptospiraemia reaches a critical threshold, leading to systemic dissemination and tissue damage. The resulting lesions are believed to be mediated by leptospiral toxins or toxic cellular components¹. 

Interestingly, not all infections lead to overt clinical disease. Subclinical infections with persistent renal colonization can occur, contributing to prolonged environmental shedding. However, when clinical disease manifests, it commonly involves renal and hepatic dysfunction, which may be reflected in laboratory abnormalities such as proteinuria and bilirubinuria^1,3. 

Diagnostic Insights: Beyond Clinical Signs 

Traditional diagnosis often relies on serology and culture, but emerging approaches such as rapid urinalysis can provide early clinical clues. Detection of protein and bilirubin in urine has been associated with successful infection and organ involvement^1,3. 

It is important to interpret these findings carefully. For instance, mild bilirubinuria may be physiological in adult male dogs with concentrated urine¹. However, a sudden increase following exposure strongly suggests pathological involvement. 

Clinical Implications for Veterinary Practice 

From a practical standpoint, veterinarians should: 

• Maintain a high index of suspicion in endemic areas  

• Recognize dogs as both patients and sentinels  

• Incorporate routine screening tools like urinalysis in suspected cases  

• Educate pet owners about environmental exposure risks  

The zoonotic potential underscores the importance of personal protective measures during handling of suspected cases. 

Conclusion 

Canine leptospirosis is not merely an infectious disease, it is an ecological and public health concern. With diverse serovars, complex transmission dynamics, and variable clinical expression, veterinarians must adopt a comprehensive, evidence-based approach. Early recognition, informed by epidemiological awareness and practical diagnostics, remains the cornerstone of effective management.  

References 

1. Klaasen HL, Veen MV, Dorrestein-Spierenburg CM, Cao Q. An assessment and comparison of the efficacy of two licensed tetravalent Leptospira vaccines for dogs using an improved challenge model. Vaccines. 2022 Sep 5;10(9):1472. https://www.mdpi.com/2076-393X/10/9/1472 

2. Grippi F, Giudice E, Di Pietro S, Sciacca C, Santangelo F, Galluzzo P, Barreca S, Guercio A. Leptospira interrogans serogroup Sejroe serovar Hardjo in aborting cows: Two herd cases in Sicily (Italy). Journal of Veterinary Research. 2020 Mar 24;64(1):73. https://sciendo.com/2/v2/download/article/10.2478/jvetres-2020-0021.pdf 

3. Schuller S, Francey T, Hartmann K, Hugonnard M, Kohn BJ, Nally JE, Sykes J. European consensus statement on leptospirosis in dogs and cats. Journal of small animal practice. 2015 Mar;56(3):159-79. https://www.academia.edu/download/87094227/Schuller_et_al-2015-Journal_of_Small_Animal_Practice.pdf